[Management of bronchiolitis in the infant. Recommendations. Long text].
Stagnara
J
J
Balagny
E
E
Cossalter
B
B
Dommerges
J P
JP
Dournel
C
C
Drahi
E
E
Gauchez
H
H
Guillot
F
F
Javault
D
D
Lagardère
B
B
Le Masne
A
A
Lesprit
E
E
Maidenberg
M
M
Maufroy
D
D
Picherot
G
G
Renaud
H
H
Robert
J
J
Undreiner
F
F
D000208:Acute Disease; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001990:Bronchiolitis, Viral / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy* / Q000821:virology; D001993:Bronchodilator Agents / Q000627:therapeutic use; D018450:Disease Progression; D004338:Drug Combinations; D005602:France / Q000453:epidemiology; D006760:Hospitalization; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010092:Oximetry; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods; D012138:Respiratory Therapy / Q000379:methods; D012307:Risk Factors; D012720:Severity of Illness Index; D013148:Spironolactone; D013449:Sulfonamides
D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D001993:Bronchodilator Agents; D004338:Drug Combinations; D013449:Sulfonamides; D013148:Spironolactone; C026063:spironolactone, althiazide drug combination